AnaptysBio: Fully Valued; With Major Litigation Uncertainty (NASDAQ:ANAB)

seekingalpha.com · 2026-10-13

AnaptysBio gets a Hold rating as its ~$1.4B market cap closely matches sum-of-the-parts fair value, with litigation risk justifying caution. Read more on ANAB.

Read the full story at seekingalpha.com →